(Bloomberg Quicktake, 11/23/20) Once deemed dangerous and illegal, psychedelic ("mind-manifesting") compounds have been rediscovered by the scientific, medical, and psychiatric communities as research reveals their capacity to help patients with a range of maladies -- including depression. With investors beginning to flood this new market with capital, will Big Pharma join in or try to squash a nascent revolution of the mind?
All materials on this site are submitted by editors and readers. All images, unless otherwise noted, were taken from the Internet and are assumed to be in the public domain.
In the event that there is still a problem, issue, or error with copyrighted material, the break of the copyright is unintentional and noncommercial, and the material will be removed immediately upon presented proof.
Contact us by submitting a comment marked "private."
Do not follow this journal if you are under vinaya or parental restrictions. Secure protection by Sucuri.
Wisdom Quarterly: American Buddhist Journal is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 United States License. Permissions beyond the scope of this license may be available at creativecommons.org/about/licenses.
No comments:
Post a Comment